Lung Cancer Research Review, Issue 42

In this issue:

Australian lung cancer screening costs
Lorlatinib for advanced ROS1-positive NSCLC
Gefitinib plus chemotherapy for EGFR-mutated NSCLC
Crizotinib for MET-dysregulated or ROS1 rearranged NSCLC
NSCLC and the immune microenvironment
Very high PD-L1 expression and response in NSCLC
Alectinib and ALK mutation status in NSCLC
Ceritinib plus nivolumab for ALK-mutated NSCLC
Nivolumab vs nivolumab plus ipilimumab in SCLC
Robotic-assisted surgery for lung cancer resection in older patients

Please login below to download this issue (PDF)